media – Page 283 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Medtronic in exclusive talks for $7B sale of units to private equity

Dive Brief The private equity firm Carlyle Group is leading the race to buy Medtronic’s connected patient monitoring and respiratory care operations, according to Reuters. Medtronic outlined plans to spin off the units almost one year ago. At the time, the company proposed creating a new connected care company, but the move reportedly led to interest from potential buyers including Siemens Healthineers and GE HealthCare. Now, with Medtronic nearing the end of its targeted window for completing a transaction, Reuters has reported that Carlyle has entered into exclusive negotiations to buy a majority stake in the two businesses at a valuation of more than $7 billion. Dive Insight Patient monitoring and respiratory interventions, part of Medtronic’s Medical Surgical portfolio, are among the slower-growing parts of the company. While neither business has the type of growth profile that Medtronic is targeting, they could be attractive to another company. According to Reuters, ...
- Source: https://www.medtechdive.com/news/medtronic--7b-deal-private-equity-carlyle-group/695282/
- 225
- October 3, 2023
Community Colleges Help Address Skills Gap

By Jennifer Markarian Pictured: Illustration of students sitting at a table/iStock, undrey Although the biopharma industry tends to focus on high-skill workers with advanced science and engineering degrees, just over half of entry-level jobs in the U.S. life sciences require skills considered middle and lower level that could be filled by people with less than a four-year degree, according to a recent report on life sciences workforce trends by the Coalition of State Biosciences Institutes (CSBI), which promotes bioscience education and workforce development, and research group TEConomy Partners. “The share of middle-skills workers needed for entry-level positions in life sciences has held steady over the past decade,” Liisa Bozinovic, chair of CSBI, told BioSpace. Individuals with degrees from the U.S. network of two-year Advanced Technical Education biotechnology programs, which provide hands-on, industry-relevant training, have been successfully filling these positions, she added. Organizations Collaborate to Promote Biotech Education InnovATEBIO, a National ...
- Source: drugdu
- 193
- October 3, 2023
Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust?

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year. By FRANK VINLUAN A Travere Therapeutics drug that won speedy approval early this year for a rare autoimmune kidney disorder has failed to meet the key goal of its confirmatory study. Still, the biotech points to data trends favoring patients treated with its drug, Filspari, and it aims to seek full approval. But even if the FDA permits the drug to remain on the market, the disappointing trial results reported Thursday call into question the commercial prospects of a product once projected to become a blockbuster seller. Filspari was developed to treat immunoglobulin A nephropathy (IgAN), in which the buildup of antibodies in the kidneys damages these organs. The FDA awarded ...
- Source: drugdu
- 163
- October 3, 2023
Novo Nordisk and Valo Health agree deal worth up to $3.3bn

Novo Nordisk has announced that it has entered into a partnership with Valo Health, worth up to $60m, to discover and develop new treatments for cardiometabolic diseases. The collaboration aims to utilise Valo’s Opal Computational Platform and real-world patient dataset, as well as its artificial intelligence (AI)-enabled small molecule discovery and its human tissue modelling platform, Biowire, to accelerate discovery and development. The Opal Computational Platform is an integrated, end-to-end drug discovery and development platform that is designed to enable a fully integrated and efficient approach for targeting and advancing candidates to regulatory approval. As part of the agreement, Valo will receive an upfront payment and a potential near-term milestone payment of $60m, as well as milestone payments for up to 11 programmes totalling up to $2.7 billion, plus research and development funding and potential royalty payments, said Novo Nordisk. Valo will enable the identification and validation of novel druggable ...
- Source: drugdu
- 124
- October 1, 2023
Landscape review reveals £1.1bn of UK funding for rare diseases

The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) have published a landscape review report, revealing that £1.1bn has been invested in UK research for rare diseases. The report findings aim to help focus areas for future funding and better target the needs of people with rare diseases. The review found that the NIHR and MRC accounted for almost £627m in funding across 698 studies between 2016 and 2021 for rare disease research. Comprised of 7,000 different types, rare diseases affect around 3.5 million people in the UK. The report revealed that motor neuron disease received the most funding in the portfolio, accounting for 8%, followed by Huntington’s disease (5%) and then preeclampsia (5%). Other diseases that received significant funding included cystic fibrosis (4%), frontotemporal dementia (4%) and idiopathic pulmonary (3%). Over five years, approximately £99.7m out of the nearly £627m of investment was ...
- Source: drugdu
- 211
- October 1, 2023
NHS Confederation research supports investment in NHS services

Report shows that if health service invests in community services hospital admissions will reduce Research commissioned by the NHS Confederation shows that the more the health service budget is invested in priming community services the more it decreases hospital admissions – bringing further savings across the wider NHS. Key figures show that for every £100 spent in the NHS community care sector, delivering care to patients closer to and in their own homes, there is a £131 return on investment in acute sector savings. This money would typically have been spent providing care to patients in hospitals and across acute services. The findings show how those areas of the country that spent less on community care in terms of population need have also seen – on average – higher levels of hospital and emergency activity, compared to those spending more. Indeed, those of the 42 integrated care systems that invested ...
- Source: drugdu
- 104
- October 1, 2023
Roche scores—again—in hemophilia drug patent case against Takeda

In a patent case centered on two rival hemophilia medicines, Roche’s Genentech unit has scored its second straight win. After a U.S. district court last year ruled in favor of Roche and invalidated a patent held by Takeda’s Baxalta unit, the U.S. Court of Appeals for the Federal Circuit reaffirmed the ruling. In the decision, U.S. Circuit Judge Timothy B. Dyk wrote that in order to be valid, patents must describe inventions “in such full, clear, concise and exact terms” so that any skilled person can make and use the same product “without undue experimentation.” In this case, Baxalta’s patent describes an antibody that binds to a protein that’s key to enable blood clotting. In its appeal, Baxalta argued that skilled practitioners can use a screening process that doesn’t amount to undue experimentation. But the circuit court shot down this argument, supporting the decision that the patent should be invalidated. ...
- Source: drugdu
- 188
- October 1, 2023
analysts

Six months after Travere Therapeutics’ Filspari won an accelerated nod to treat patients with a rare kidney disease, the first-of-its-kind drug narrowly failed its confirmatory trial. While the results bode poorly for a full FDA approval anytime soon, Travere may take some solace in the fact that the drug’s removal from market looks unlikely, at least according to two groups of analysts. The readout comes from Travere’s phase 3 PROTECT study pitting Filspari (sparsentan) against the popular angiotensin II receptor blocker irbesartan in patients with primary immunoglobulin A nephropathy (IgAN). In the study, Filspari failed to reach statistical significance over irbesartan when it came to kidney function outcomes as measured by the estimated glomerular filtration rate (eGFR). It wasn’t all bad news for Filspari, which demonstrated long-term kidney function preservation and achieved a clinically meaningful difference on the eGFR slope versus irbesartan. The drug also hit statistical significance on its ...
- Source: drugdu
- 158
- October 1, 2023
Parkinson’s UK calls on government to mark World Patient Safety Day

The report outlines ways the government can help patients with Parkinson’s disease Parkinson’s UK has called on the government to take action to help people with Parkinson’s disease (PD) get their medication on time in hospital, as part of its relaunched ‘Get It On Time’ campaign to mark World Patient Safety Day on 17 September. The charity, alongside Diabetes UK, Epilepsy Action, National Aids, Rethink Mental Illness and the Richmond Group, supported by the Royal College of Emergency Medicine and the Royal Pharmaceutical Society, outlined in a joint statement how the government can take action to help patients with PD. PD is a progressive neurological condition which affects an estimated 128,000 people in England. People living with PD can experience severe harm to their health, such as trauma, as a result of not receiving their medication on time while in hospital. The issue also affects patients living with diabetes, epilepsy ...
- Source: drugdu
- 133
- October 1, 2023
Cancer Research UK invests £123m in Scotland

The investment will support research into cancer treatments and diagnosis Cancer Research UK (CRUK) has announced its largest ever investment of £123m in Scotland as part of a seven-year commitment to the CRUK Scotland Institute. The institute, which is facilitated in partnership with the University of Glasgow, will use the investment to support research into new and improved cancer treatments and diagnosis, as well as bolster Scotland as a major global hub for cancer research. It will also aid in attracting research talent to the Scotland Institute and will support major studies into specific types of cancer that largely affect Scotland’s population, including liver, pancreatic, bowel and lung. Despite mortality rates falling by 8% in the past decade, more than 34,000 people are diagnosed with cancer every year in Scotland. Previously known as the CRUK Beatson Institute, the CRUK Scotland Institute studies the roots of how cancer begins, the genetics ...
- Source: drugdu
- 113
- October 1, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.